A model for building a national, patient-driven database to track contraceptive use in women with rare diseases

J Am Med Inform Assoc. 2022 Jan 12;29(2):348-353. doi: 10.1093/jamia/ocab224.

Abstract

Data on the safety and effectiveness of contraception among women with rare diseases are critical and sorely lacking. To fill this gap, we propose a national, patient-driven database that tracks contraceptive safety and effectiveness among women with rare diseases. We built a pilot database focusing on women with cystic fibrosis in 3 phases: (1) database design input from patients and experts, (2) merging of contraceptive survey data with relevant clinical outcomes from the Cystic Fibrosis Foundation Patient Registry (CFFPR), and (3) forming a data guide to facilitate accessible output data. We successfully linked 62 contraceptive survey variables with 362 relevant clinical outcome variables for 150 patients. This pilot represents a breakthrough in linking contraceptive data to disease-specific outcomes and informs how to build a national, patient-driven contraceptive database for women with rare diseases.

Keywords: contraception; cystic fibrosis; database; rare disease; registries.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Contraception
  • Contraceptive Agents*
  • Cystic Fibrosis*
  • Databases, Factual
  • Female
  • Humans
  • Rare Diseases

Substances

  • Contraceptive Agents